The American Academy of Ophthalmology defined Optic Neuritis (ON) as the swelling of the eye's optic nerve. The optic nerve carries light signals from the back of the eye to the brain so that a person can see. A person cannot see clearly if the optic nerve is swollen, damaged or is infected. It is a rare acute disorder which usually occurs in one eye, and is characterized by the symptoms including blurring of vision, a loss of part or all of central vision, reduced colour vision, and dimness of vision.
Most patients with Optic Neuritis have eye pain which characteristically worsens with movement of the eye. Optic Neuritis is most common among adults, aged 20 to 40 years, and its symptoms generally improve in 80 per cent of patients over a few weeks.
More females are affected than males, and approximately five out of every one-hundred thousand people are affected by Optic Neuritis every year [Thomas C. Weiss et al., 2018].
Optic Neuritis is most common among adults, aged 20 to 40 years, and its symptoms generally improve in 80 per cent of patients over a few weeks.
More females are affected than males, and approximately five out of every one-hundred thousand people are affected by Optic Neuritis every year
As per The Transverse Myelitis Association, Optic Neuritis is a rare condition with an estimated annual incidence of 6.4 per 100,000 cases in the population in the United States. The occurrence of Optic Neuritis tends to be the highest in communities located in higher latitudes (in the northern US and Western Europe) and is the lowest in regions closer to the equator.
Some of the key players in the Optic Neuritis Treatment Market includes Biogen, Mitochon Pharmaceuticals, Noveome Biotherapeutics and others.
For more details visit: https://www.delveinsight.com/report-store/optic-neuritis-market
#OpticNeuritis #vision #neuritisoptica #eyes #InvisibleIllness